Sarah Jane Tribble joined Kaiser Health News from Ideastream — the NPR/PBS member station in Cleveland, Ohio — where she covered health, health policy and the business of health care. She won an Emmy as host of the station’s health care programming and was a regular contributor on NPR’s Morning Edition and All Things Considered.
The issue of conflicts of interest has become more pressing in recent years as drug prices soar and healthcare companies reach out to the academic and policy community for advice — often with generous payments attached, ethics experts say.
In his plans to cut sky-high drug prices unveiled Friday, Trump said that increasing industry competition will help Americans save at the pharmacy counter.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
President Donald Trump has railed against the high price of prescription drugs, yet many Americans aren’t seeing a change in what they pay out-of-pocket. Here’s a look at the rhetoric thus far versus the results.
The story of Korlym highlights how America’s drug development system can turn an old drug into a new one that treats relatively few — but often very desperate — patients.
The White House’s proposal, which comes after Congress passed a two-year spending deal last week, sets the tone for the administration’s focus on prescription drugs.
At a hearing held by the Senate Health, Education, Labor and Pensions Committee, experts made nine proposals to lower drug prices. Here's an analysis on the likelihood of action being taken on each of them.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The 340B program requires pharmaceutical companies to give steep discounts to hospitals and clinics that serve high volumes of low-income patients. But a move by CMS to cut Medicare payments for hospitals enrolled in the program has sparked a debate over the program's future.
Medicare officials requested comments late Thursday on how to use discounts and rebates to help decrease what enrollees pay for prescriptions.
The United States is one of the few developed countries without regulations on prescription drug pricing.
The Food and Drug Administration is changing the way it approves medicines known as “orphan drugs” after revelations that drugmakers may be abusing a law intended to help patients with rare diseases.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Behind-the-scenes partnerships between the pharmaceutical industry and advocacy groups may work against lowering the cost of high-priced drugs.
Reports of five- and six-figure annual price tags for orphan drugs have concerned U.S. senators.
Sens. Orrin Hatch (R-Utah), Chuck Grassley (R-Iowa) and Tom Cotton (R-Arkansas.) raised the possibility that regulatory or legislative changes might be needed “to preserve the intent of this vital law” that gives drugmakers lucrative incentives to develop drugs for rare diseases.
Emflaza, the brand name for deflazacort, has never been approved for sale in the United States, but the steroid has been sold for decades in other countries — at much lower prices
In a statement, Grassley said the inquiry is “based on reporting from Kaiser Health News” and strong consumer concern about high drug prices.